REVTx-99
REVTx-99 is a nasal solution for the prevention and/or treatment of respiratory viral infection and chronic nasal congestion.
Sixty seven percent (67%) of subjects in our Phase 1 healthy volunteer study showed a greater than 5-fold increase in IP-10. Three-fold changes in IP-10 have been shown to be protective against influenza and rhinovirus infection in other clinical studies. Additional information can be found in our corporate presentation.
Background PREVTx-99a Phase 1 Study Safety and Biomarker Results REVTx-99a Phase 2 Viral Challenge Study
REVTx99b Phase 1 Allergen Challenge Study
Background
Figure 1
The innate immune system is our first line of defense against invading pathogens such as bacteria and viruses. When a respiratory pathogen, such as a virus, invades a person through the nose, the innate immune system responds by producing and releasing various types of cytokines. Cytokines are proteins that direct different activities in cells to combat the invading pathogen.
REVTx-99a, our lead therapeutic candidate, is a broad anti-viral nasal drop solution that can be used to prevent or treat respiratory viral infections, including Influenza A, Influenza B, parainfluenza, rhinovirus, respiratory syncytial virus and SARS-CoV-2 including its variants. REVTx-99a is thought to work by boosting the body’s innate immune system to produce local nasal protective cytokines (Figure 1), but not systemic cytokines that could worsen a patient’s condition. These protective cytokines work in multiple ways to blunt the ability of an invading pathogen (such as a virus) from surviving and proliferating.
REVTx-99b may also be helpful in treating allergic rhinitis and chronic nasal congestion by activation of the same protective cytokines.
The active ingredient in REVTx-99 is Phosphorylated hexaacyl disaccharide (PHAD®) (a synthetic version of monophosphoryl lipid A or MPLA). PHAD® is also known generically as glucopyranosyl Lipid A (GLA). REVTx-99 is formulated as a liquid for intranasal administration.